Psoriatic Disease

Psoriasis is not only a disease that impacts patients physically, with scars and red patchy skin, but it also impacts patients emotionally. Patients’ mental health often suffer due to the anxieties of living with the condition.

The word “gaslighting” has taken on a life of its own in recent years, being used in the context of interpersonal relationships, political discourse and online chatter alike.

Adult patients with active psoriatic arthritis who received risankizumab reported sustained improvements in skin and joint symptoms at week 100 in two ongoing phase 3 trials, according to data released by AbbVie.

Patients with psoriatic arthritis may consider tapering once treatment goals are reached, according to guidance from the Group for Research and Assessment of Psoriasis and Psoriatic Arthritis published in Nature Reviews Rheumatology.

Guselkumab demonstrates sustained benefits for multiple, diverse manifestations of psoriatic arthritis through 1 year, according to data published in Rheumatology.

The FDA has approved a citrate-free, 100 mg/mL formulation of the Humira biosimilar Hadlima, according to a statement released by Samsung Bioepis and Organon.

Janus kinase, or JAK, inhibitors have been used in the treatment of rheumatological disorders, including psoriatic arthritis. Their benefit in psoriatic skin disease is still being studied, however some safety concerns have kept the class of drugs as a second-line treatment option.

In this issue of Healio Psoriatic Disease, we focus on JAK inhibitors.

The emergence of drugs inhibiting the JAK-STAT pathway has culminated in tyrosine kinase 2 inhibitors targeting psoriatic arthritis, lupus and other indications, noted a presenter at the 2022 Association of Women in Rheumatology conference.

The FDA has approved ustekinumab for the treatment of children aged 6 years and older with active psoriatic arthritis, according to a Janssen press release.